1,135 reports of this reaction
3.2% of all ZIPRASIDONE HYDROCHLORIDE reports
#2 most reported adverse reaction
WEIGHT INCREASED is the #2 most commonly reported adverse reaction for ZIPRASIDONE HYDROCHLORIDE, manufactured by ROERIG. There are 1,135 FDA adverse event reports linking ZIPRASIDONE HYDROCHLORIDE to WEIGHT INCREASED. This represents approximately 3.2% of all 35,561 adverse event reports for this drug.
Patients taking ZIPRASIDONE HYDROCHLORIDE who experience weight increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT INCREASED is moderately reported among ZIPRASIDONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to weight increased, the following adverse reactions have been reported for ZIPRASIDONE HYDROCHLORIDE:
The following drugs have also been linked to weight increased in FDA adverse event reports:
WEIGHT INCREASED has been reported as an adverse event in 1,135 FDA reports for ZIPRASIDONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT INCREASED accounts for approximately 3.2% of all adverse event reports for ZIPRASIDONE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience weight increased while taking ZIPRASIDONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.